Disc Medicine Inc. Announces Initiation of Phase 2 Study for DISC-3405 in Polycythemia Vera with Initial Data Expected in 2026
Reuters
Aug 07
<a href="https://laohu8.com/S/IRON">Disc Medicine</a> Inc. Announces Initiation of Phase 2 Study for DISC-3405 in Polycythemia Vera with Initial Data Expected in 2026
Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced significant updates in its research and development programs. The company is on track to submit a New Drug Application (NDA) for bitopertin in the treatment of erythropoietic protoporphyria $(EPP.UK)$ under the accelerated approval pathway by October 2025. This submission follows a successful pre-NDA meeting. Additionally, Disc Medicine anticipates initial data from its Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) and multiple dose data from a Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in the fourth quarter of 2025. The company has also initiated a Phase 2 study of DISC-3405 in polycythemia vera, with initial data expected in 2026. The clinical data from the continuation phase of the Phase 1b trial of DISC-0974 in MF anemia was presented at EHA 2025, demonstrating a durable hematologic response. These developments indicate continued progress across Disc Medicine's pipeline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001816736-25-000006), on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.